Navigation Links
Mast Therapeutics Hosting 2nd Annual Sickle Cell Disease Therapeutics Conference On September 19, 2013
Date:9/6/2013

can be found on the conference web site at www.scdconference.com.  

About Mast Therapeutics

Mast Therapeutics, Inc. is a publicly traded biopharmaceutical company headquartered in San Diego, California.  The Company is leveraging the MAST (Molecular Adhesion and Sealant Technology) platform, derived from over two decades of clinical, nonclinical and manufacturing experience with purified and non-purified poloxamers, to develop MST-188, its lead product candidate, for serious or life-threatening diseases with significant unmet needs.  MST-188 is a cytoprotective, hemorheologic, anti-inflammatory and anti-thrombotic agent that has potential utility in diseases or conditions characterized by microcirculatory insufficiency (endothelial dysfunction and/or impaired blood flow).  

The Company is enrolling subjects in EPIC, a pivotal phase 3 study of MST-188 in sickle cell disease.  The Company plans to initiate a phase 2 clinical study of MST-188 in acute limb ischemia, a complication of peripheral arterial disease, in early 2014.  More information can be found on the Company's web site at www.masttherapeutics.com.

Mast Therapeutics™ and the corporate logo are trademarks of Mast Therapeutics, Inc.

Forward Looking Statements

Mast Therapeutics cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that are based on the Company's current expectations and assumptions. Such forward-looking statements include, but are not limited to, statements regarding the Company's development plans for MST-188 in acute limb ischemia, including the timing of initiation of the planned phase 2 study.  Among the factors that could cause or
'/>"/>

SOURCE Mast Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
3. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
4. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
5. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
6. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
7. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
8. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
9. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
10. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
11. New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... Inc. (Nasdaq: ISIS ) today reported net income ... and six months ended June 30, 2015, respectively, compared ... million for the same periods in 2014. Isis, significantly ... than $90 million of revenue Isis earned in the ... to license  ISIS-FXI Rx .  Isis increased its cash ...
(Date:8/4/2015)... FLORHAM PARK, N.J. , Aug. 4, ... partnered with University of Massachusetts Medical School,s ... enhancements and support regarding clinical protocols and ... Workflow Platform. Specialty medication ... ArmadaOne and helps to ensure optimal patient ...
(Date:8/4/2015)... -- Delcath Systems, Inc. (NASDAQ: DCTH ), a specialty ... an emphasis on the treatment of primary and metastatic ... studies in Europe and the ... Delivery System (CHEMOSAT) will be presented at the upcoming ... be held in Marseille, France , ...
Breaking Medicine Technology:Isis Reports Financial Results And Highlights For Second Quarter 2015 2Isis Reports Financial Results And Highlights For Second Quarter 2015 3Isis Reports Financial Results And Highlights For Second Quarter 2015 4Isis Reports Financial Results And Highlights For Second Quarter 2015 5Isis Reports Financial Results And Highlights For Second Quarter 2015 6Isis Reports Financial Results And Highlights For Second Quarter 2015 7Isis Reports Financial Results And Highlights For Second Quarter 2015 8Isis Reports Financial Results And Highlights For Second Quarter 2015 9Isis Reports Financial Results And Highlights For Second Quarter 2015 10Isis Reports Financial Results And Highlights For Second Quarter 2015 11Isis Reports Financial Results And Highlights For Second Quarter 2015 12Isis Reports Financial Results And Highlights For Second Quarter 2015 13Isis Reports Financial Results And Highlights For Second Quarter 2015 14Isis Reports Financial Results And Highlights For Second Quarter 2015 15Isis Reports Financial Results And Highlights For Second Quarter 2015 16Armada Health Care collaborates with University of Massachusetts Medical School for ArmadaOne Specialty Pharmacy Platform 2Armada Health Care collaborates with University of Massachusetts Medical School for ArmadaOne Specialty Pharmacy Platform 3Delcath Announces Acceptance of Abstracts for Presentation at the European Association of Dermato Oncology Annual Congress 2Delcath Announces Acceptance of Abstracts for Presentation at the European Association of Dermato Oncology Annual Congress 3Delcath Announces Acceptance of Abstracts for Presentation at the European Association of Dermato Oncology Annual Congress 4
... Jan. 17, 2012 SIPP International Industries Inc. ... food and beverage, hospitality and medical technology industries announced ... FVJ Holdings, a Japanese Consulting firm based in Osaka ... begin generating additional residual revenues within three months.  ...
... HealthCare today announced latest data on its investigational compound ... Co lo r ectal cancer treated with re ... t herapy) trial. The study met its primary ... by 29% (HR=0.77, p=0.0052, median OS: 6.4 months vs. 5.0 ...
Cached Medicine Technology:SIPP International Industries, Inc. to Acquire Controlling Interest in FVJ Holdings out of Osaka Japan 2Phase III Data Show Bayer's Investigational Compound Regorafenib (BAY 73-4506) Met Primary Endpoint Showing Statistically Significant Improvement in Overall Survival in Patients with Metastatic Colorectal Cancer Refractory to Standard Approved Thera 2Phase III Data Show Bayer's Investigational Compound Regorafenib (BAY 73-4506) Met Primary Endpoint Showing Statistically Significant Improvement in Overall Survival in Patients with Metastatic Colorectal Cancer Refractory to Standard Approved Thera 3Phase III Data Show Bayer's Investigational Compound Regorafenib (BAY 73-4506) Met Primary Endpoint Showing Statistically Significant Improvement in Overall Survival in Patients with Metastatic Colorectal Cancer Refractory to Standard Approved Thera 4Phase III Data Show Bayer's Investigational Compound Regorafenib (BAY 73-4506) Met Primary Endpoint Showing Statistically Significant Improvement in Overall Survival in Patients with Metastatic Colorectal Cancer Refractory to Standard Approved Thera 5
(Date:8/5/2015)... ... August 05, 2015 , ... Stelari introduces their new collection, The ... with their new line, The Earth’s Song. Combining fashion and activewear, Stelari’s new collection ... Inspired by the Australian Outback, this collection is sure to make the spirit seeker ...
(Date:8/5/2015)... FR (PRWEB) , ... August 05, 2015 , ... Available ... versatile new serum formulated with a quartet of beauty-enhancing marine and plant oils. A ... it features rose oil which stands out for its lovely scent and soothing properties. ...
(Date:8/5/2015)... (PRWEB) , ... August 05, 2015 , ... Over 6,500 ... days of competition and camaraderie at the Special Olympics World Games 2015 (July 25 ... the largest international sporting competition held in Los Angeles since the 1984 Olympics, and ...
(Date:8/4/2015)... ... 05, 2015 , ... In reaction to a pending NYS ... gas (LPG) next to Seneca Lake*, the full Executive Committee of 1199SEIU United ... strongly opposes that permit. *, ** , “1199SEIU healthcare workers have always been ...
(Date:8/4/2015)... ... 05, 2015 , ... The National Association of Professional ... its VIP Woman of the Year Circle. She is recognized with this prestigious ... for professional women, boasting more than 700,000 members and over 200 operating Local ...
Breaking Medicine News(10 mins):Health News:Stelari: Bohemian Chic Activewear Line 2Health News:Stelari: Bohemian Chic Activewear Line 3Health News:Phytomer launches ROSÉE SOIN Radiance Replenishing Oil 2Health News:Phytomer launches ROSÉE SOIN Radiance Replenishing Oil 3Health News:Phytomer launches ROSÉE SOIN Radiance Replenishing Oil 4Health News:CPMA Member Podiatrists Ensure Fit Feet at the Special Olympics World Games in Los Angeles 2Health News:CPMA Member Podiatrists Ensure Fit Feet at the Special Olympics World Games in Los Angeles 3Health News:Opposition Mounting to Permit Liquid Propane Gas Storage Next to New York’s Seneca Lake 2Health News:Opposition Mounting to Permit Liquid Propane Gas Storage Next to New York’s Seneca Lake 3Health News:NAPW Inducts Deborah Stevens, Executive Assistant to Chairman and CEO at Mirion Technologies, Inc., Into its VIP Woman of the Year Circle 2
... hospitals to effect a charge on cancer patients for ... //system, is being seriously considered by Ontario's Health Minister. ... We've done some due diligence and obviously we're closer ... believe it's the right thing said in a telephone ...
... Association has released a set of new recommendations and ... in the rapid access issue of Stroke: Journal of ... leading cause of death and a major source of ... people in the United States suffer a stroke, resulting ...
... conducted by The Royal College of Midwives has revealed that ... labor room//. Nearly 38% of the 1400 female respondents said ... ,Surprisingly, one in four fathers who were inside ... birth process while one in six mothers felt their husbands ...
... in the teaching hours for medical subjects such as ... pathetic state where medical students are unable to locate ... confusing one organ with another. In addition to the ... in the teaching hours for biochemistry, pathology, physiology and ...
... launched the Female Condom (FC) in India. It has partnered ... to market// their female condoms in India under the brand ... research before being able to launch the condom in India. ... first year. A pair of Confidom will cost Rs.250/-., ...
... the teenagers in the recent years. But a new study ... they ever took such vows. // ,The study ... way of gauging how well they adhere to these pledges, ... of public or written declarations to remain a virgin until ...
Cached Medicine News:Health News:How To Prevent A Stroke 2Health News:How To Prevent A Stroke 3Health News:How To Prevent A Stroke 4Health News:Australian Medical Students Lack Anatomy Knowledge 2Health News:Teenagers Often Deny Taken ‘Virginity Pledges 2
This is an antigen-capture assay intended for the detection of histidine-rich protein ll (PfHRP-ll), which is released from Malaria-infected red blood cells....
Malaria P.f. Rapid Test Device...
The Malaria Combo Test is a rapid test for the qualitative detection of Plasmodium falciparum and / or Plasmodium vivax , Plasmodium ovale and Plasmodium malariae antigen in whole blood. This ...
Core Malaria Pv/Pf is a self performing, qualitative, sandwich immunoassay for the detection and differentiation of vivax malaria and falciparum malaria in whole blood samples....
Medicine Products: